Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Intellia Therapeutics (NTLA) Accumulated Depreciation & Amortization (2016 - 2025)

Intellia Therapeutics has reported Accumulated Depreciation & Amortization over the past 11 years, most recently at $58.6 million for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 17.94% to $58.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.6 million through Dec 2025, up 17.94% year-over-year, with the annual reading at $58.6 million for FY2025, 17.94% up from the prior year.
  • Accumulated Depreciation & Amortization was $58.6 million for Q4 2025 at Intellia Therapeutics, up from $49.7 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $58.6 million in Q4 2025 and troughed at $26.1 million in Q4 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $39.9 million (2023), against an average of $41.5 million.
  • Year-over-year, Accumulated Depreciation & Amortization skyrocketed 35.09% in 2021 and then rose 17.94% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $26.1 million in 2021, then increased by 27.13% to $33.2 million in 2022, then increased by 20.07% to $39.9 million in 2023, then increased by 24.66% to $49.7 million in 2024, then rose by 17.94% to $58.6 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Accumulated Depreciation & Amortization are $58.6 million (Q4 2025), $49.7 million (Q4 2024), and $39.9 million (Q4 2023).